APLS 2017 Annual Report

88 APELLIS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended December 31, 2015 2016 2017 Operating expenses: Research and development $ 13,730,311 $ 22,978,599 $ 40,303,878 Cost of acquired in-process research and development 26,486,000 — — General and administrative 6,356,782 4,303,743 10,463,151 Operating loss (46,573,093) (27,282,342) (50,767,029) Loss from remeasurement of fair value of warrants — — (153,692) Interest income (expense), net 50,853 135,309 (96,915) Other income, net 6,284 22,396 11,542 Net loss and comprehensive loss $ (46,515,956) $ (27,124,637) $ (51,006,094) Net loss per common share, basic and diluted $ (8.03) $ (3.22) $ (3.68) Weighted-average number of common shares used in net loss per common share, basic and diluted 5,795,040 8,428,366 13,870,949 See accompanying notes to consolidated financial statements